all tumor entities treated with an oral antitumor drug C00-D48
Conditions
Interventions
Group 1: Control Group: Intensified clinical-pharmaceutical/pharmacological care primarly via consultations on-site
The clinical-pharmaceutical/pharmacological care includes medication management, sid
Sponsors
Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Initiation of therapy with an oral antitumor drug, cancer diagnosis, adult patient, planned therapy duration/estimated lifespan of at least 4 months, ability to independently complete questionnaires, technical requirements: internet, camera, microphone, and speakers on the device used for videocalls.
Exclusion criteria
Exclusion criteria: Lack of german language skills, patients unable to give consent, cognitive impairments that prevent adequate study participation, missing written consent, patients who are not able to take their medicine on their own, pregnant/breastfeeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| drug-related problems (DRP; side effects and unresolved medication errors) related to oral antitumor therapy within 12 weeks, patient satisfaction with therapy (TSQM Ver. II Questionnaire) after 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life (EQ-5D-5L Questionnaire), severe side effects (CTCAE = Grade 3) related to overall medication, overall survival, combined endpoint of severe side effects (CTCAE =3), treatment discontinuation, unscheduled hospital admission, and all-cause mortality between week 0 and week 12 | — |
Countries
Germany
Contacts
Public ContactAMBORA-Team
Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg
Outcome results
None listed